摘要
目的:研究利福平运用于菌阳性老年肺结核治疗中的价值及对炎症因子的影响。方法:选择本院2016年10月-2018年6月纳入的92例菌阳性老年肺结核患者,按照数字表法随机分为两组,每组46例。研究组采取常规治疗+利福平,对照组采取常规治疗,对比两组治疗结果。结果:研究组治疗1、3个月病灶吸收率分别为58.70%、89.13%,明显高于对照组36.96%、71.74%(P<0.05)。治疗前两组的IL-6、IL-10、TNF-α、CD4^+及CD4^+/CD8^+水平相比,差异均无统计学意义(P>0.05),治疗后两组均明显改善(P<0.05),且研究组各指标水平均优于对照组(P<0.05)。治疗前两组的生理职能、躯体疼痛、社会功能、情感职能评分相比,差异均无统计学意义(P>0.05),治疗后两组均明显改善(P<0.05),且研究组各项评分均高于对照组(P<0.05)。研究组不良反应发生率6.52%,与对照组的4.35%相比,差异无统计学意义(P>0.05)。结论:利福平运用于菌阳性老年肺结核中效果明显,促进炎症反应消退,提高生活质量,并不会增加不良反应发生率,安全性高。
Objective:To study the effect of Rifampicin in the inflammatory factors for elderly patients with positive mycobacterium tuberculosis.Method:A total of 92 elderly patients with positive mycobacterium tuberculosis treated from October 2016 to June 2018 in our hospital were selected and randomly assigned to study group and control group,46 cases in each group.The control group was given the conventional therapy,the study group was given the conventional therapy plus Rifampicin.The therapeutic effects of two groups were compared.Result:After treatment 1 and 3 months,the focal absorption rate in the study group was 58.70% and 89.13% significantly higher than those of the control group with 36.96%,71.74%,the differences were statistically significant(P<0.05).Before treatment,the levels of IL-6,IL-10,TNF-α,CD4^+ and CD4^+/CD8^+ between groups were not significantly different(P>0.05);after treatment,the related levels for two groups were sharply improved(P<0.05),the related levels in the study group were better than those in the control group(P<0.05).Before treatment,the scores of role physical,bodily pain,social function and role emotional between groups were not significantly different(P>0.05);after treatment,the above scores for two groups were sharply improved(P<0.05),the above scores in the study group were higher than those in the control group(P<0.05).The adverse event rate between study group(6.52%)and control group(4.35%)was not significantly different(P>0.05).Conclusion:Rifampicin can remarkably increase the therapeutic effect,relieve the inflammatory response,improve the quality of life and clinical safety,and produce no obvious effect in the adverse event rate.
作者
张晓琦
ZHANG Xiaoqi(Jiamusi Tumor Tuberculosis Hospital,Jiamusi 154007,China)
出处
《中国医学创新》
CAS
2019年第27期39-42,共4页
Medical Innovation of China
关键词
炎症因子
菌阳性
利福平
肺结核
临床疗效
Inflammatory factors
Positive mycobacterium tuberculosis
Rifampicin
Pulmonary tuberculosis
Clinical effect
